The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 billion, representing an increase of 6.7% year over year.The current level reflects a downward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Ahea ...

CHONGQING, CHINA - JULY 13: In this photo illustration, a smartphone displaying the logo of Johnson ... More & Johnson (NYSE: JNJ), a leading American multinational corporation known for pharmaceuticals, medical devices, and consumer health products, is held in front of a screen showing the company's latest stock market chart on July 13, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)Getty Images Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. ...

Key Takeaways ABT's Q2 revenues are projected at $11.07B, up 6.7% year over year; EPS is estimated to rise 9.6% to $1.25. ABT's Medical Devices likely drove growth, led by CGMs, cardiac devices and TMVR system approval. Nutrition and EPD segments are expected to post modest to solid year-over-year revenue gains. Abbott Laboratories (ABT) is slated to report second-quarter 2025 results on July 17, before the opening bell.The company delivered adjusted earnings per share (EPS) of $1.09 in the last quarter, ...

Key Takeaways BIO unveils four new ddPCR systems, enhancing its Life Science offerings post-Stilla Technologies acquisition. BIO's new systems improve workflow, precision and throughput across PCR applications in key research areas. BIO sees strong adoption of ddPCR tools, aided by recent investments and platform expansions in 2024.Bio-Rad Laboratories (BIO) recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ...

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel®, a novel hydrogel-based radioactive therapy designed to deliver targeted radiation to solid tumors. This comprehensive submission, supported by extensive animal and human data, marks a significant milestone in Vivos Inc.’s ...

Core Insights - Firefly Neuroscience, Inc. is collaborating with Heidelberg University Hospital to study the neurophysiological impact of 15q13.3 copy number variants (CNVs) [1][3] - The study utilizes Firefly's FDA-cleared technology to analyze EEG data from 30 subjects, aiming to uncover insights into brain function related to rare genetic conditions [2][3] - The collaboration reflects a commitment to advancing precision neuroscience and aims to bridge the gap between genotype and phenotype for better patient care [3] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, with a proprietary technology called Brain Network Analytics (BNA™) [7][8] - The company has built a comprehensive database of brain wave tests over the past 15 years and has achieved FDA clearance for its technology [7][8] - Firefly is targeting pharmaceutical companies and medical practitioners for the commercial launch of its BNA™ technology [7] Study Objectives - The study aims to identify electrophysiological biomarkers associated with 15q13.3 CNVs [6] - It will characterize neurocognitive profiles linked to deletions versus duplications of the chromosomal region [6] - The research supports future diagnostic and therapeutic strategies for neurodevelopmental disorders [6]

Core Points - Artivion, Inc. experienced a data breach on or about November 20, 2024, involving unauthorized access to its network [3] - The breach potentially compromised sensitive personal data, including names, Social Security Numbers, driver's license numbers, and direct deposit details [3] - Edelson Lechtzin LLP is investigating the incident and considering a class action lawsuit for affected individuals [4] Company Overview - Artivion, Inc. is a global medical device company based in Kennesaw, Georgia, founded in 1984 and previously known as CryoLife [2] - The company specializes in manufacturing, processing, and distributing medical devices and implantable tissues for cardiac and vascular procedures [2]

09 Jul 2025 05:00:00 ET │ 78 pages US MedTech 2Q25 Preview: But Wait, There's More CITI'S TAKE At the mid-year 2025 mark it has already been a long year, given macro- economic headlines (including tariffs) and uncertainty the new normal. MedTech has largely withstood the healthcare headwinds but has been caught in the macro. While tariffs seem to have been normalized or at least absorbed, with the 90-day pause on April 2 reciprocal tariffs extended to August 1, and the U.S.-China pause expiring August 12 up ...

11 July 2025 | 9:40AM CST China Healthcare: Jun 2025 China hospital equipment bidding: Growth on hold as ASP pressure unfolds, less expectation from stimulus in 2H We continue to track the procurement value of the main medical devices in China. Although the June bidding value data maintained a YoY growth rate of 49%, it still came in below our previous expectations due to a 3% MoM decline. We believe the decline was primarily driven by lower unit prices as a result of VBPs - continuing the trend observed in ...

South Korea medical students end 17-month boycott of classes https://t.co/q6wbI28Vts ...